MedTrace Logo

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

NCT04750616 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 304

Last updated 2025-03-12

No results posted yet for this study

Summary

A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery

Conditions

Interventions

DRUG

Niacinamide

Niacinamide 3 grams on the day of surgery and post-surgical days one and two

DRUG

Placebo

Matched placebo on the day of surgery and post-surgical days one and two

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Beth Israel Deaconess Medical Center

    collaborator OTHER

  • Cedars-Sinai Medical Center

    collaborator OTHER

  • Kaiser Permanente

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-13
Primary Completion
2025-04-30
Completion
2025-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04750616 on ClinicalTrials.gov